1035217-17-4Relevant academic research and scientific papers
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
Bradbury, Robert H.,Callis, Rowena,Carr, Gregory R.,Chen, Huawei,Clark, Edwin,Feron, Lyman,Glossop, Steve,Graham, Mark A.,Hattersley, Maureen,Jones, Chris,Lamont, Scott G.,Ouvry, Gilles,Patel, Anil,Patel, Joe,Rabow, Alfred A.,Roberts, Craig A.,Stokes, Stephen,Stratton, Natalie,Walker, Graeme E.,Ward, Lara,Whalley, David,Whittaker, David,Wrigley, Gail,Waring, Michael J.
, p. 7801 - 7817 (2016)
Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical
